Analysts think CTXR stock price could increase by 124%
Dec 05, 2024, 12:26 PM
9.89%
What does CTXR do
Citius Pharmaceuticals, based in Cranford, NJ, specializes in critical care products, particularly in oncology and anti-infectives. Its key products include LYMPHIR, Mino-Lok, Halo-Lido, Mino-Wrap, and NoveCite.
3 analysts think CTXR stock price will increase by 124.18%. The current median analyst target is $8.16 compared to a current stock price of $3.64. The lowest analysts target is $8.08 and the highest analyst target is $8.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
